DAMORA THERAPEUTICS, INC. Increase (Decrease) in Other Noncurrent Liabilities
DAMORA THERAPEUTICS, INC. (DMRA) reported Increase (Decrease) in Other Noncurrent Liabilities of -$1.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-30 was $53.00K, a 562.50% increase year-over-year.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-31 was -$54.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was -$21.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was $1.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for fiscal 2025 was -$15.00K, a 134.88% decline from fiscal 2024.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for fiscal 2024 was $43.00K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 3 month as first filed | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$1.00K 10-Q · filed 2026-08-10 | -$22.00K derived: sum of 3 quarters · filed 2026-08-10 | -$21.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$54.00K 10-Q · filed 2026-05-12 | -$75.00K derived: sum of 2 quarters · filed 2026-05-12 | -$74.00K derived: sum of 3 quarters · filed 2026-05-12 | -$66.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$20.00K derived: sum of 2 quarters · filed 2026-03-19 | -$12.00K derived: sum of 3 quarters · filed 2026-08-10 | -$15.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.00K derived: sum of 2 quarters · filed 2026-08-10 | $6.00K 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $5.00K 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | -$3.00K 10-Q · filed 2026-05-12 | $2.00K 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $43.00K 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |